Consequently, our study challenges current guidelines on the duration of antithrombotic treatment after AVR surgery with biological valves by presenting results suggesting that these patients will gain from an additional 3 months of warfarin treatment in terms of reduced cardiovascular death without risking a significant increase in bleeding events.
FORBES: Longer Warfarin Therapy After Bioprosthetic Aortic Valve Replacement May Be Beneficial